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Abstract Genome-wide Sequencing provides an exciting opportunity for the future of genetic
counseling. However, the efficacy of GWS in covering G-C rich regions of DNA, detection of
variants, coverage of the exome, reanalysis, and identifying disease origin in non-coding regions
of DNA remains to be proven. GWS provides a diagnostic success rate of 36-73% in pediatric
cases and 50-67% of adult rare disease and alters the path of necessary care offered by genetic
counselors. Limitations significantly hamper the success of GWS in a genetic counseling setting,
such as difficulties in obtaining consent for testing and data storage, the high rate of incidental
findings, cost of testing and insurance coverage, and underrepresentation in high-need
populations. Additional large-scale studies are required to provide empirical evidence for the
diagnostic ability of GWS along with the development of tools for genetic counselors to
effectively provide clinical and psychosocial care for clients and institutional standards for variant
calling and the handling of incidental findings.
1. INTRODUCTION
Since the Human Genome Project’s initial publication in 2003,
human genome sequencing has evolved far beyond its origins as a
multi-year, multi-billion dollar venture. Today genome-wide
sequencing (GWS) can be completed for less than a thousand
dollars1 and yields results in as little as 24 hours2,3. Indeed, the
availability of genomic sequencing is reflected in the publications
of such large-scale studies such as the 10,000 Genome Project,
The Cancer Genome Atlas Program, and the UK 100,000
Genomes Project. The American College of Medical Genetics
(ACMG) has stated their support of genetic testing and genomic
medicine’s use in the clinical setting3. Genomic analysis has
tremendous implications for medicine and has been of particular
relevance to the field of genetic counseling. In the last decade, the
use of GWS using traditional technologies has been studied for its
ability to compete with other next-generation sequencing
techniques, ability to identify molecular mechanisms for rare and
undiagnosed disorders, identifying suspected genetic illness in
neonates, and pharmacogenetic possibilities. Many of these
studies take place in a clinical setting where genetic counselors
are, or should be, present to ascertain patient consent, inform
decisions, and provide psychosocial care prior to and after results
have been received. As the availability of genomic sequencing
and the public and medical use of such tests increase, genetic
counselors will inevitably face genomic medicine in clinical
practice. The goal of this review is to identify the state of GWS as
a diagnostic tool genetic counselors may use and elucidate the
current state of GWS in clinical practice, outlining benefits, best
practices, and concerns.
2. GENOME-WIDE SEQUENCING
There is a significant gap in the research created by the lack of
any large-scale study (>1000) comparing genome-wide
sequencing directly against current methodologies, such as
targeted next generation sequencing (NGS), chromosomal
microarray (CMA), or whole-exome sequencing (WES). In the
limited current literature, most studies compare only the rate at
which GWS provides a diagnosis of pathogenic variants within
the exome, rather than the overall diagnostic ability or inclusion
of portions of the genome not covered by WES. While it is
critical to affirm the diagnostic comparability of GWS, neglecting
any diagnosis from within non-coding regions of DNA is to
ignore the clear possible advantage of this method. Despite the
gap in research, this section will discuss the current state of GWS
and analyze the claims made by proponents of GWS that it is
better than current standards at analyzing G-C rich regions of
DNA, variant detection (CVNs and SNVs), covers exon regions
more completely, is superior in identifying the cause of disease,
and has a significant advantage over other methods due to the
ability to identify mutations in non-coding regions of the genome
and the availability of re-sequencing.
Guanine-Cytosine Rich Regions
One of the most notable improvements to genome-wide
sequencing responsible for increasing clinical utility was the
development of polymerase chain reaction (PCR)-free techniques.
Although the use of PCR is known to result in amplification bias
due to the process of recombination2,4, it is the primary method
for assembling data in WES, and only one study evaluating the
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efficacy of PCR-free WES was found by the author 5. Using PCR
for GWS has been shown to be less effective than WES at
correctly mapping G-C rich sections of the exome 6,7. WES only
targets roughly 1-2% of the genome, creating a much smaller
margin of error when compared to GWS which covers >90% of
the genome8. This PCR-free method of sequencing is the
strongest case made for the improvement of G-C rich region
capture by GWS. A 2015 study comparing 48 WES samples
against 52 GWS samples from different individuals found GWS
performed slightly better across G-C rich regions except in where
content was exceptionally high: in this case GWS capture also
suffered. This study was limited in cohort size as well as
sequencing reliability, due to using data from multiple sources.
The authors note that the lower rate of WES was possibly tied to
the number of PCR steps used in the sequencing technique which
varied across samples9. A 2017 study analyzing areas of reduced
coverage in 400 patients who underwent WES and 100 who
received GWS showed areas of high G-C content to reduce
coverage but did not specify the difference in efficacy between
the two sequencing techniques10. A larger study from the same
year by Carss et al. (2017) studied 722 sets of patient data. The
majority (650) of these patients had GWS in addition to or instead
of WES, and showed GWS to be significantly more effective at
covering the genes with a high G-C content (45-65%) when
compared to WES. GWS was able to reach a higher read depth
and showed much less variability than WES. Specifically this was
used to elucidate a pathogenic variant of GUCY2D which resulted
in inherited retinal disease (IRD) that would have been missed by
WES alone11. The claim that GWS is significantly better at
covering G-C rich regions than WES has a mechanical basis and
shows promise, but more empirical evidence is needed before this
claim can be validated.
Superior Variant Detection
An appealing potential for the use of GWS is an improved rate of
detection for single nucleotide variants (SNVs) and structural
variants, including copy-number variants (CNVs), indels, and
inversions. More sensitive testing has the potential to identify the
cause of unknown or undiagnosed genetic diseases12 and lead to
more effective medical intervention.
In a study of 100 patients, GWS was shown to have a
34% rate of identifying the cause of genetic disease, a four-fold
increase over CMA which achieved diagnosis in only 8% of
patients22. A perhaps more convincing meta-analysis from 2018
summarizing 37 studies (total 20,068 patients) found both WES
and GWS to be significantly more effective at diagnosing children
with suspected genetic disease. The study acknowledges,
however, no significant difference in efficacy between WES and
GWS in the studies analyzed. It is of note that two of the 37
studies showed a non-significant difference, likely due to the
smaller sample size: these studies had a combined cohort of 138
while the average sample size for the other studies was >500 17.
Truly, the closest competitor to GWS is WES, likely
owing to the fact that they both cover the portion of the genome
responsible for the majority of disease-causing mutations 13, 14.
The diagnostic success rate for WES ranges from 23% to 87%
and is difficult to generalize as the results range widely depending
on size of the study, patient phenotype, presence of consanguinity,
and other factors. There is a similar range for GWS patients, also
greatly affected by the scope and size of study. Despite these
challenges, there are those who claim GWS will soon be the
clinical standard as a first-tier diagnostic test for patients with
anticipated genetic disorder15, 16, 17, 18. Studies have borne this out
with varying success. In 2015 both WES and GWS were run on 6
unrelated individuals with congenital asplenia and found that
while both tests resulted in a similar number of SNVs, 91% of
those detected by WES were thought to be false positives due to
errors in alignment or mapping. While GWS had a lower
expected false positive rate, it was still undesirably high at 25%.
Despite the small size of the study and the lack of diversity in
patients, it suggests GWS may be more effective at accurately
identifying SNVs within the exome19. In a study by Lionel et al.
(2018), analyzing the genomes of 103 individuals with unknown
suspected genetic disease GWS was able to diagnose pathogenic
variants in 41% of participants, nine of which were structural
variants missed by previous WES16. While the cohort size was
still small, the diagnostic rate across seven distinct phenotypes
and three inheritance patterns. A 2016 study of patients with IRD
compared the diagnostic effect of targeted next-generation
sequencing against GWS, finding GWS was able to identify the
pathogenic variant in 24 of the 33 patients, more than targeted
NGS methods13. The identified pathogenic variants included those
found in non-coding regions, insertions, and deletions20. Another
study conducted genome-wide high-resolution SNP array in 99
fetuses displaying a congenital heart defect. A significant number
of CNVs were identified in 19 of the fetuses with variants of
unknown significance in only 3% 21. Additionally, genome-wide
association studies (GWAS) show promise in detecting new
variants related to illness or disease risk, including 44 areas of
interest for major depression23, and 170 in breast cancer, which
include some non-coding regions24.
Not all studies have shown positive indications for
GWS, however. The aforementioned meta-analysis 17 showed no
significant difference between WES and GWS. A retrospective
analysis by Gross et al. (2019) on 17 individuals who had both
CMA and GWS, evaluating the ability of each method to identify
CNVs, showed GWS did not perform significantly better than
CMA 18. A retrospective analysis out of Saudi Arabia of patients
with unknown genetic disease showed the limited utility of GWS,
as there was not a significant benefit over using WES. GWS was
able to identify seven pathogenic variants out of 108, whereas
WES identified five25. In a study of 100 individuals, GWS
outperformed WES in some respects but was not significantly
better at identifying pathogenic variants in the exome 9. A review
by Wilson, Miller, and Rousseau (2017) stated the analytical
validity of GWS is weak, due to instability of technical platforms
and lack of quality regulation across platforms as well as the
range of interpretation methodologies26. A 2017 study provided
an array of possibilities for text functionality to create a unifying
significance of variants, but so far no one system has been
employed enough to achieve unity across clinics27.
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More Complete Exon Coverage
The use of PCR in sequencing is relevant to exome analysis as
well as in the analysis of G-C rich regions of DNA. In addition to
improving the areas of high GC content, using PCR-free GWS
methods allows for greater general coverage of the exon region of
the genome25, 28. A 2014 study showed GWS was able to cover
74.8% of the exome at a depth of 40x, much higher than the 48%
40x depth accomplished by WES29. However, some disagree with
this claim and report exome coverage at 100x for ~95% for WES
and GWS 30x for the entire genome30. This is likely due to
discrepancies in technology at the time of publication. Other
studies point to the uniformity of coverage made possible by
GWS to make their claim that GWS will replace WES, stating
that the methods required to create similar uniformity in WES
would be complex6. GWS is also said to be free of bias when
compared to WES, and a 2015 study analyzed both methods with
three different metrics. WES showed bias in all three metrics,
while GWS did not show bias9. However, one study claimed to
find no significant relationship between the coverage of
sequencing and ability to diagnose pathogenic variants31. Yet
another study showed GWS to do “considerably better” than
WES at sequencing the exome with the ability to achieve a 95%
rate of SNV detection with a uniform average of 14 reads2. Some
of the discrepancies in the data may result from varying use in
technology and from a conflicting method of interpreting variants.
In 2015, the ACMG updated their guidelines on variant calling
standards which may clear up some confusion in subsequent
studies32. However, the wide range of results indicates a
significant need for clear guidelines on sequence calling as well
as additional large-scale studies assessing PCR-free WES
coverage against GWS coverage across the entire exome.
Ability to Reanalyze Data for New Diagnosis
Proponents of GWS in a clinical setting have mentioned the
potential benefit of resequencing the genomes of patients who did
not receive a diagnosis in the first round of testing. Storing
genomic data and periodically reinvestigating it for variants
discovered in the intervening years without having to reorder
testing or inconvenience a patient, additionally reducing cost,
time, and discomfort of conducting targeted gene panels and other
tests to target variants of formerly unknown significance, has
obvious appeal15, 16. Reassessment of existing data is no more
difficult than the original analysis33. Many patients without
diagnosis are identified to have a variant of unknown significance
(VUS). These may be reclassified over time with more
information to be benign, likely benign, likely pathogenic, or
pathogenic. The knowledge base around genomic information is
rapidly accumulating, suggesting that new publications and the
classification of VUS could lead to new diagnosis and
identification of molecular pathogenicity if genomic patient data
is regularly re-evaluated.
In a study of GWS in 100 children with an undiagnosed
disorder, only 36% received a diagnosis on the first test. Despite
ongoing clinical care, new diagnoses were made only when the
genomic data was reanalyzed two years later, yielding seven more
diagnoses. From this research, the authors suggest this 5-fold
increase over CMA and 3-fold increase in diagnostic yield
compared to other sequencing methods warrants reanalysis of
genomic data for pediatric patients with undiagnosed genetic
disease every 1-2 years until a diagnosis is found or the
phenotype progresses33.
Although reanalysis of GWS has the added advantage
over CMA, targeted gene panels, and WES due to the volume of
data: When the whole genome is present there is the ability to
identify genes which had not been targeted by panels or WES,
such as the HMGA2 gene33. However, this is a slight advantage as
new genes are rarely identified. Some evidence suggests
reanalysis of WES is no more effective at diagnosing unidentified
disease than GWS. For example, the previously discussed study
out of Saudi Arabia from Alfares et al. (2018) also measured the
effect of reanalysis. In their study, reanalyzing all 108 genomes
resulted in the diagnostic yield for GWS decreasing from nine to
seven, four of which were also identified by reanalyzing the WES
data25. Considering the discrepancy in the difficulty of
reanalyzing an exome versus a genome, the authors suggest it is
more efficient to reanalyze any available exome data before
running or reanalyzing GWS. One study reanalyzed existing
genomic and exomic data for 371 patients with developmental
delay (DD) after three years. The original success rate in
diagnosis for GWS was higher (26.2%) than WES (22%), but
after the interval of three years, WES showed a significantly
higher identification rate of 11%, while GWS only identified
1.6%34. With these findings, the authors propose a 6-part
framework for reanalysis which includes strategies for reanalysis,
prioritization, timelines, and data-sharing techniques.
It is not clear if GWS reanalysis has significant
advantage over reanalysis of WES. A 2019 study conducted
reanalysis of data sets from two studies. In the first, manual
reanalysis of 250 patients' exome data yielded a diagnostic rate of
46.8%. Despite this high rate of success, the authors caution that
manual reanalysis may not be feasible in large-scale projects, as
this was conducted over a period of five years by a team of staff.
In the second study, 2000 patient exome data was analyzed
through an automated process and is possibly responsible for the
smaller diagnostic yield of 36.7%35. In another study, 101 exomes
of patients who had died of unexplained sudden death or
idiopathic disease were reanalyzed after 1-7 years, identifying 3
new variants for the rare disease patients and 1 sudden death
case36.
Mutation Identification in Non-Coding Regions
Another enticing aspect of GWS is the potential for illuminating
diseases caused by mutations in non-coding regions of DNA 9, 15.
The ENCODE project determined a large portion of the
non-coding genome is active37, and mutations in regulatory
elements such as promoters, enhancers, operons, silencers,
non-coding RNA, or insulators could lead to disease38,39,40.
Mutations in non-coding regions are also associated with
tumorigenesis, such as the TERT telomerase promoter region
which is present in ~70% of melanomas41. This presents a clear
advantage over WES and would be most competitive with
targeted NGS. However, the non-coding regions of the human
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genome and the mechanisms of action are still being researched38.
This method would rely heavily on large, population-specific
reference panels in order to be effective, the existence of which is
limited but growing40. This method of analysis presents hope for
individuals with unknown cancers and suspected genetic disease,
but is not yet a viable clinical option. The development of
large-scale population-specific data banks, as well as thorough
analysis across a diverse range of populations to identify the
biological mechanisms of non-coding DNA, will need to be
established before the impact of GWS on diagnosis through the
use of noncoding regions can be understood. Without this
required background information, promising the results of
elucidating molecular causes for disease through analysis of
non-coding regions of DNA would be making a false promise.
3. USE IN CLINICAL PRACTICE
In this section the current state of genome-wide sequencing in
clinical practice will be evaluated, specifically assessing the
current efficacy of GWS in pediatric care and rare disease
diagnosis as well as what the evidence says on the role of the
genetic counselor in genomic interventions.
Use in Pediatric Medicine
Much of the research conducted on the efficacy of genome-wide
sequencing is within the pediatric population. Neonates and
young children with genetic illness may not express all clinical
features of the disorder which limits facilitation of diagnosis
through current hypothesis-guided practices, such as targeted
NGS22,42. Additionally, the rapid pace of disease progression
establishes a demand for diagnosis sooner rather than later43.
Having a confirmed diagnosis serves to alter medical
intervention, either guiding more effective treatments or halting
unnecessary ones3. The wide array of information gained by GWS
combined with the lowering cost and short processing time of
such tests creates an opportunity for hope in a uniquely stressed
population.
In the 2018 study mentioned previously (see: Superior
Variant Detection), a cohort of 103 pediatric patients with
undiagnosed genetic disease were tested to compare GWS against
other traditional testing methods. To qualify for the study patients
must have undergone single-gene testing, CMA, WES, or another
NGS test without reaching diagnosis or likely pathogenic
variants. GWS was able to identify the origin of disease in 41% of
the cohort. Additionally, 70 participants also underwent WES for
comparison which was outperformed by GWS16. The authors also
suggest due to rapidly accumulating information regarding VUS
those in the cohort who did not receive diagnosis should have
their genomic data reanalyzed every 2-3 years. The same year, a
study from a dysmorphology clinic of 60 pediatric patients
showed a diagnostic success rate of 68.3% and included SNVs,
and CNVs. The description of the manner in which these
diagnosis resulted in alteration of the patient’s clinical treatment
was particularly illuminating. It included referrals to specialists,
imaging, voiding muscle biopsy, and in once case of a family who
received a diagnosis of neuronal ceroid lipofuscinosis, a transfer
to palliative care44. Farnaes et al. (2018) found a diagnosis in 43%
of 42 critically ill infants using GWS, and the genomic data was
used additionally to avoid morbidity in 26% of all infants, major
morbidity in 10%, and reduced the likelihood of mortality in 2%,
reducing cost for both the providing hospital and families.
Additionally, GWS was correlated with reducing time spent in
hospital by an estimated 124 days as well as time spent in
intensive care units. The presence of GWS altered treatment
modalities for 13 of the children, which included starting new
medications, stopping medications for an anticipated diagnosis
that was wrong, and altering three major surgery plans45. This
demonstrates the effect not only of correct diagnosis through
GWS, but that the elimination of certain disease possibilities can
alter care and reduce morbidity in a vulnerable population. A
similarly small cohort study of 35 critically ill infants showed a
diagnosis of genetic illness through GWS in 57% of patients, with
four patients who achieved diagnosis receiving positive effects on
medical management. An additional six patients received a
diagnosis that influenced palliative care decisions. Among the
diagnosed newborns the 120-day mortality rate was 57%, a
number difficult to quantify as no other studies identified included
this data46. It should be noted, however, that older studies such as
Stravropoulos et al. (2015) did not indicate a significantly higher
success rate of GWS compared to WES in a study of 100
pediatric patients22. Finally, a systematic review of next
generation sequencing (including WES, GWS, CMA, and
Standard testing) on 4698 patients across 14 studies showed a
diagnosis rate of 30%-73% while alternative testing methods
ranged from 3%-40%, and listed their opinion that GWS should
be used as a first-tier diagnostic test especially in high-risk
newborns who have need for rapid, effective, widespread testing
to prevent further morbidity or mortality3. While the numbers
range greatly, much of the hope is placed within the portion of the
population GWS can serve. The ability to reduce morbidity,
mortality, alter medical interventions, and inform decision making
for a vulnerable population such as critically ill neonates forms
the basis of many defenses of GWS use in this capacity47. Indeed
this reflects the experience of the genetic counselor more closely:
while large-scale studies and number-crunching are required to
inform the evidence based medicine genetic counselors practice,
ultimately the clinical genetic counselor will be working one on
one with families, providing individualized medical
recommendations and psychosocial support. In this situation the
emphasis is placed on serving the patient and their family, even
with varying rates of diagnostic success.
The diagnostic possibilities of GWS within this target
population raises the question of universal use or inclusion in
newborn screening, particularly due to the rapid progression of
disease and the subsequently shortened timeline for diagnosis 17.
Using GWS for infants with genetic conditions has benefits
beyond a straightforward diagnosis, as this data could be used for
pharmacogenetic (choosing treatment plans based on personalized
genomic medicine made available through testing) and donation
purposes (HLA typing, etc.). In a study of 98 pediatric patients
who underwent GWS as part of the diagnostic odyssey a targeted
analysis of SNPs and indels around the GYP2D6 gene and other
genes also responsible for metabolizing drugs commonly used in
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a clinical setting, providing information that led to clinical
changes to treatment in 95 of participants48. GWS has capabilities
for HLA-typing as well with possibility for deeper immunological
analysis as well as more effective tissue and organ donation
matching49. Some argue NGS should be universally available for
all who may benefit42, while others caution against immediate
launch, instead suggesting more research on which diagnosis
actively benefits patients and improving turnaround time for
genomic testing and interpretation45. Friedman et al. (2017)
argues GWS must conclusively prove to be both cost
effectiveness and reliably distinguish pathogenic variants from
benign, as well as rectify ethical concerns of consent, incidental
findings, and safe storage of data (see Limitations) before GWS
should be used in newborn screening50.
Despite the ACMG recommendation against using GWS
for fetal testing, the field is evolving. These tests are primarily
conducted through amniocentesis or chorionic villus sampling
and can be used as both a diagnostic tool and mechanism of
precision medicine, despite the logistical challenges and ethical
dilemmas associated with such testing51,52,53.
Use in Rare Disease Diagnosis
The second-most popular area of research into the efficacy of
GWS is rare disease diagnosis. Sharing much of the appeal with
pediatric use, GWS has the potential to end the long and
expensive process often referred to as the diagnostic odyssey. If
GWS were to show empirical evidence of greater efficacy than
WES it would be a boon to this target population. Seventy-nine
people comprising 16 distinct families with an undiagnosed
genetic illness underwent GWS with a diagnostic success rate of
62.5%. Two of the remaining families received a suspected
diagnosis, and four remained unknown. Of the diagnosed
diseases, the molecular cause of pathogenicity included missense
mutations, nonsense mutations, CNV, SSR, compound
heterozygous mutations and a frameshift deletion, across six
inheritance patterns. This rate of success was achieved through
what they described as steps beyond primary filtering methods,
having only detected the cause of mutation in five families.
Retrospective analysis and case-by-case study increased the
diagnostic yield to 62.5%. The authors note the diagnosis resulted
not only in alterations to medical treatment which included
targeted medical intervention for children, halting disease
progression in some cases, and ended or avoided unnecessary or
harmful treatments, but also allowed for prenatal counseling and
for action to be taken in a disease which caused early
menopause54. A study from 2014 conducted GWS on 217 families
with an undiagnosed suspected genetic disorder from an extensive
range of phenotypes found pathogenic variants in only 21% of
cases. Despite the low rate of detection, the variants included
nonsense, missense, noncoding, frameshift, and splicing
variants31. IRD has been the target of two studies. The first
surveyed a phenotypically heterogeneous cohort of 605 patients
who had not found the molecular mechanism of disease through
other testing, primarily WES or targeted gene panels. GWS
identified the pathogenic variant in 56% of the participants,
including variants in CG rich regions of DNA, deletions,
duplications, and three SNVs in noncoding regions of the
genome. Nineteen additional genes previously unknown to
associate with IRD were identified as possibly contributing to
pathogenicity 11. Due to the complex nature of phenotype and
genotype heterogeneity of RD, patient outcomes were not
identified as part of this study. However, the inheritance pattern is
difficult to ascertain from phenotype alone without confirming the
genetic source of illness. It can be reasoned that the knowledge of
inheritance patterns could inform patient family planning
decisions and decrease morbidity in future generations. The
second, smaller study conducted GWS on 52 patients (46 with
diagnosed IRD, six control) with a success rate of 50%, and
similarly found two additional likely pathogenic variants and
three pathogenic variants not detected by targeted NGS. These
variants also ranged across protein coding regions, noncoding
regions, indels, and new genes of interest20. These IRD studies
highlight the potential for GWS to improve diagnostic accuracy
similar to the claims made throughout the first section of this
paper.
Role of the Genetic Counselor
Despite the claim some studies make that in the near future all
health professionals will be faced with genomic technologies and
be asked to convey the results and management of genomic
testing54, 56, 57, 58, it does little to negate the necessity of genetic
counselors. The utility of genetic counseling, particularly for
pediatric and rare disease populations, is well documented.
Patients with children in the neonatal intensive care unit
experience higher rates of depression, anxiety, and emotional
distress as well as lower coping and perceived social support
compared to the general population, These families are in need of
the psychosocial counseling genetic counselors are trained to
provide56, 59. Additionally, the acute care setting of the NICU
generates differences in patient need from traditional clinical
care60. The uncertainty and distress faced in this community is
similarly found in populations undergoing extensive diagnostic
odyssey61. Several studies indicate patients who receive genetic
counseling pre and post NGS results demonstrate more complete
understanding of results, decision making, and less distress than
patients who did not receive counseling15, 62, however others still
describe difficulty in “managing expectations and anticipating
family response”61. One study aimed to develop an effective
method for facilitating patient’s choices around genome wide
sequencing of children with undiagnosed suspected genetic
condition. This online tool, DECIDE, combines original and
established content from other research projects to balance
necessary information with “decision aids” to be used in tandem
with genetic counseling and shows a possible direction for
effective counseling around GWS64. Indeed, the 2014 guidelines
from the ACMG states any panel surveying the 56 genes with
known pathogenic association require additionally thorough pre-
and post-test counseling for the patient61, 65.
When a diagnosis is achieved through GWS/NGS,
genetic counselors continue to provide psychosocial support
navigating the new diagnosis, including empowering medical
decision making, social or familial implications, and connecting
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patients with specialists or other local programs56, 61, 62. Other
studies highlight the utility of genetic counselors in circumstances
where a diagnosis is not reached. Genetic counselors are
necessary to provide insight so patients can make informed
decisions. Additionally, the emotional distress which can arise at
a lack of definitive diagnosis cannot be overlooked. The studies
referenced in this paper demonstrate the high risk of one such
possibility and can result in feelings of “chaos” and “emotional
and financial desperation.” To put patients at risk of such
outcomes without providing psychosocial support violates ethical
nonmaleficence62, 66.
The increased risk of secondary findings and other
consequences of genomic analysis provide some additional
difficulties for the genetic counselor67 (See: Limitations). One
such challenge, although perhaps unexpected, was the
development and use of direct to consumer genomic testing.
While direct to consumer testing (DTC) often presents an exciting
opportunity for patients, they are a poor substitute for GWS
offered by licensed clinicians due an absence of regulation in
DTC laboratories, issues regarding disclosure of efficacy, and
interpretation68. This DTC has created an emerging patient
population with specific questions clinicians may face. One study
conducted by Schmidt et al. discussed the issue of DTC genomic
testing and the unique pressure this testing can put on those
private practice genetic counselors patients are inevitably faced
with. A first hand account from three such genetic counselors, this
study examined the experience of dealing with patients who have
sought out counseling as a result of tests and interpretations
purchased independent of a clinical setting with variable
interaction with medical professionals. The average experience of
DTC testing is difficult to characterize, as they vary in cost,
quality of testing, contact by medical professional, and the
manner of information they receive with some tests including
interpreted data and others returning raw data which may then be
uploaded to other interpretive software, which may or may not be
associated with the original company from which the test was
purchased. Interpretation from both testing companies and outside
crowd sourced reference software vary in regards to the method
of identifying and classifying variants. Problems with this system
include the lack of uniformity or clinical validity in the
interpretive software which has gone through no peer reviewed
analysis and provides no explanation for how to interpret the risk
of any variation detected. As such, this step is what leads patients
into the office of a clinician. In the experience of the counselors
interviewed, patients come to a genetic counselor after DTC
genomic testing for one of three reasons: they are in good health
but seek counseling to be proactive, they have a specific health
concern related to family history (such as cancer, heart disease,
pathogenic variants, etc.), or they are currently ill and
undiagnosed. Each population presents different needs in the
genetic counseling setting69. A small study from a population
focus group suggests patients value the ability to access DTC
testing and regulations and should be an area of training for future
genetic counselors58.
4. LIMITATIONS
GWS is not a part of the average genetic counselor’s repertoire,
and as such there are few genetic counselors trained in gaining
consent for and interpreting results of GWS. The cost, turnaround
time, storage and informatics burdens, high risk of incidental
findings, and the challenge of data interpretation are all areas of
concern and hindrance for genetic counselors 22, 31, 56, 70. Of
particular concern is the variance of unknown significance. VUS
can be the source of much anxiety for patients, as the specificity
of GWS makes it difficult to identify a normal SNV from a
pathogenic SNV62, and their status may change from likely benign
to likely pathogenic, or from likley pathogenic to benign, as
studies further develop30. The challenge presented by VUS has
been a cause for genetic counselors to avoid work with GWS17, 56,
62. Additionally, the access to the tools needed for GWS and
interpretation are a hindrance for genetic counselors as they are
not widely available62. Additionally of note is the 2014
recommendation from the ACMG against GWS/WES for prenatal
counseling, citing the time of testing as a limitation. While this is
a problem for cancer genetic counselors as well, some still do this
work71.
Despite the evident utility of genetic counseling in
genome-wide sequencing, there remain logistical, economic, and
ethical concerns which must be addressed before GWS can be
widely adopted. These include the disparity in establishing patient
consent and safe storage of genomic data, handling of incidental
findings, expense to the patient, unequal racial representation in
reference panels, and direct to consumer testing.
Consent and Data Storage
Establishing patient consent with large scale testing provides a
different challenge than targeted NGS or gene panel testing due to
the wider range of data provided, rate of VUS, and implications
this information may have for both patient and family members.
Consent may be difficult to ascertain due to the complex nature of
genomic medicine which often requires more background
knowledge than a single gene test or gene panel. A study by
Samuel et al. (2017) assessed the efficacy of healthcare
professional’s ability to inform patients who had genetic or
genomic testing between 2013 and 2017 through interviews with
33 patients and a series of focus group discussions with health
care professionals (including genetic counselors). The results
showed variation in information retention among the patients,
some reporting feeling empowered by the knowledge and others
only recalling signing a consent form. Commonly patients
reported understanding content at the time of appointment but
failed to recall important information, such as the consent to
sharing relevant data within the family. Patients who were in
emotional distress at the time of consultation stated more
difficulty in recalling materials discussed, and healthcare
providers in the focus group discussed offering a gap between two
consultations to allow time for emotional processing. This may be
a helpful intervention for patients when the case is not acute.
However, it is critical for genetic counselors to be aware of the
varying rate of success pre-testing consultation can have and react
accordingly. This study closes with a suggested ethical framework
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from their findings, adding to the research on ethical treatment of
patients72. Studies exploring the complexity of consent and
attempting solutions such as narrowing the focus of pre-test
consent forms are limited, but present in the literature73, 74. Current
guidelines state the pretest consultation should include the
implications of test results for both patient and families, the range
of test results possible (benign, likely benign, unknown, like
pathogenic, pathogenic), how these results would alter care and
future disease risk, as well as discussion of storage of sample and
data56. These recommendations are an evolving process with both
patient and provider input under consideration72, 73, 74. Still, some
genetic counselors find this limitation too great and believe it to
be a preventative measure for GWS in a genetic counseling
clinical setting71.
Furthermore, safety concerns regarding storage of
genomic data have been expressed by both researchers and
patients71, 72. Genomic information stored for both patients and
research participants represents a unique level of risk for patient
identification not present in other types of stored data. In addition
to the concern of a potential hack, there is a high amount of raw
data to store that some have listed may be problematic22, 71.
Considering the rise of cyber attacks targeting hospitals in the last
three years alone, the security of genomic data is a pressing
concern which must be addressed in those studies that harness
GWS75. From this information, pertinent questions are raised.
Would the additional security required to protect genomic data
come at an increased cost which would limit research/medical
availability? How important is privacy over patient care? With a
diagnostic rate around 50%, however, this poses a risk to a large
portion of the patient population who would receive GWS
without an attached diagnosis and be put at increased risk of
personal data leaking. The onus is on researchers to produce more
data on diagnostic success and morbidity rates in patients with
negative GWS diagnosis before this can be ethically deployed.
Incidental Findings
In addition to ascertaining patient understanding and consent,
there is the matter of incidental findings (IFs). Also called
secondary findings, these encompass any pathogenic or likely
pathogenic results found outside the original reason for testing
which create a conflict of medical ethics in the genetic counselor.
There are now 67 genes associated with 24 different disorders
outlined by the ACMG for monogenic disease, such as Marfan’s
syndrome and the BRCA1 and BRCA2 genes76. Due to the high
number of diseases which may be uncovered as IFs, IFs represent
a huge range of uncertainty for patients and their families. The
risk can range from low to high, disease potential may be mild to
severe, and the presentation of illness may occur within several
years or towards end of life, if they are to present at all. The task
of communicating the potential risks of IFs in order to obtain
consent or declination to receive any IFs during GWS provides an
additional layer of complexity which must be accounted for when
providing genetic counseling. One study, which examined the
factors which influence patient attitudes regarding
decision-making support from clinicians, identified several
crucial elements for clinicians aware of when providing
counseling for parents of children who qualify for GWS. These
included informational needs, specifically around the process of
receiving information rather than content. The majority of
participants reported appreciating receiving information in
smaller pieces over a longer period of time rather than a “flood”
of information. Participants provided suggestions for enhancing
support strategies for future patients in their position and were
engaged with the collaborative process and described the
importance of a trusting and collaborative relationship between
patient and provider77. IFs have been discussed widely as a
complication with WES as well, and similar methodologies for
the handling of IFs in WES may be deployed in GWS. IFs are an
area of concern especially during the testing of newborns and
young children, due to what some call a right to not be burdened
with knowledge of potential disease. Diseases such as
Alzheimer’s or Parkinson’s disease which manifests later in life
(if at all) can be a cause of medical discrimination due to
increased disease risk56, 71, 78. In 2013 the ACMG updated their
policy on incidental findings after the National Society for
Genetic Counselors and other organizations expressed concern
over the original policy stating any IFs found during WES or
GWS in the (at the time) 56 genes with associated pathogenicity
should be included in all testing reports, irrespective of patient
age or reported preference for IFs76 in order to reduce morbidity
through nonmaleficence. Ultimately the recommendation was
updated to allow patients the opportunity to opt out of receiving
IFs discovered during WES or GWS. Although they are not
official guidelines for practice, the ACMG recommendations are
respected and may act as a “temperature check” of the state of the
field79. Patients may not want to be informed of IFs for a variety
of reasons, such as insurance discrimination, cultural stigma,
anxiety, or informational overwhelm80. Additionally, one study
showed parents of children in the NICU who qualified for GWS
were significantly less likely to opt to receive IFs when compared
to the parents of older children who also qualified for GWS,
suggesting there are different motivations in across settings
genetic counselors will need to be sensitive to. As the GWS
improves diagnostic yield and scope of diagnostic range, the rate
of IFs will only increase. A small study evaluating the effect of
the ACMG update to recommendations on IFs reported the
change did not alter the clinical practice for 26 of the 34 genetic
counselors with access to WES interviewed for this study. This
was in part due to the preferences in IF reporting in the different
laboratories the counselors used. The majority of the laboratories
offered counselors the option to opt out of IFs depending on
patient preference for such information. The differences cited by
interviewed counselors in patient interaction before and after the
ACMG recommendations mentioned that the time spent with
patients pre-testing increased and the focus of their discussion
shifted at least in part. Despite what may sound like a challenge,
only 23.5% of participants considered their sessions post ACMG
recommendations to be more difficult than previously. Some cited
the sessions became easier now that they had a specific list of IFs
to discuss with the patient which they were able to structure the
consultation around80. This information could be useful for
designing institutional protocols for the education of navigating
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discussion around IFs with patients in genomic testing.
Additionally, one study highlighted the differences between IFs
identified in a clinical setting against those in a research setting.
In the research setting, the person identifying the IFs may not be a
genetic counselor, physician, or another clinically trained
individual to interpret the long-term consequences of IFs or
provide the psychosocial counseling appropriate in the context81.
While institutions will vary in their handling of IFs, there should
be recommended protocol genetic counselors can reference in
regard to which diseases have significant rates of successful
medical interventions/preventions such as those established with
BRCA1/BRCA2 and which do not, such as Alzheimers. This
might best be accomplished through a databank organizing
possible IFs and the status of treatment options, however, as the
data and treatment evolve rapidly this would need to be a closely
monitored and regularly updated source.
Expense and Insurance
The cost of GWS continues to decline, with more recent studies
acquiring testing for less than a thousand USD per genome54.
Other studies, however, are quick to establish that this low cost
does not take into account the cost of running bioinformatics, the
cost of interpretation by a trained clinician, or pretesting and
posttesting counseling for patients, which increases the cost by a
variable rate depending on the location and resources for the
study16. Still, the cost-effectiveness of GWS remains difficult to
ascertain, as in some cases it may save patients money long-term,
as in one pediatric study it was identified the cost of diagnostic
testing prior to the study was estimated to be over $19,000 USD3.
Given the varying success rate of GWS to produce reliable
diagnosis, it is unclear if this would indeed be a cost-effective
first-tier diagnostic test for children with unknown genetic
disease.
Currently, this is an unattainable option for many
patients living in the United States due to the cost of diagnosis
and evaluation without the aid of insurance. Although the cost to
the patient can be reduced through insurance companies, as of
2021 the largest insurance companies in the United States (by
membership): United Healthcare, Anthem, Aetna, Cigna, and
Humana82. None cover the cost of whole genome sequencing,
citing the validity as “undetermined” and “experimental”83, 84, 85,
86,87. United Healthcare specifically states “ [GWS] is not
Medically Necessary for evaluating any genetic disorder due to
the availability of clinically equivalent diagnostic tests.”83.
Despite this, several of these companies are participating in
experimental trials which involve the use of GWS. WES is
available through most of these plans, but GWS clearly does not
have the clinical validity in the eyes of insurance companies to
warrant inclusion, even for neonatal cases or those of rare
undiagnosed diseases. This provides a significant challenge to the
use of GWS in the genetic counseling practice, and compounds
the need for large, empirical studies to explicate the clinical utility
of whole-genome testing.
Insurance discrimination is an additional area of
concern: A study of GWS in newborns discussed some potential
participants may have declined participation in the study due to
concern for their future healthcare, as at the time of the study the
country of study did not have any nondiscrimination laws
regarding genetic test results. In total, 35% of potential
participants declined to take part in the study and could create a
bias sample population22. In order for GWS to be a realistic option
for many, legal protections against discrimination for diagnosis or
IFs against patients and family members may need to be
established before patients will feel confident using GWS.
HRG and Unequal Representation
The ability of GWS to identify the pathogenicity of a variant is
only as good as the panel against which it is measured. In order to
establish the risk associated with a variant, there must be a robust
reference panel to compare variation within this section of
genome in healthy individuals of this population10, 88. A single
Human Reference Genome (HRG) simply will not do. Indeed, a
random individual is expected to have a nucleotide variation of
4-5 million when compared to the HRG62. Additionally, when
genomes are sequenced using resequencing methods vs de novo
assembly, errors are created due to portions of the sequencing
genome unable to match with reciprocal portions of the reference
genome, resulting in incomplete mapping. One study by
Faber-Hammond and Brown found 4.3% of data from a sample of
45 genomes from individuals from nine distinct population groups
were unable to be sequenced against the HRG89. The HRG is not
the only reference material to have this problem, however, as
many of the studies listed in this paper were conducted on those
with European ancestry and only one used a control group of
healthy population members. This has created problems in several
studies mentioned previously, such as the 2019 Carss et al. study
of IRD. Underrepresented populations such as those with African
and South Asian ancestry showed a higher rate of VUS due to this
lack of representation, and noted a higher rate of genetic diversity
as well as consanguinity may have contributed to the difficulty
and expose the need for more representation in genetic profiling
11. Furthermore, populations with high rates of consanguinity
present additional diagnostic challenges as the rates of
coinheritance of multiple disease and allelic heterogeneity are
higher in these populations, already underrepresented in genomic
panels, making diagnosis even more difficult90.
Only a select number of studies have committed to
sampling a diverse population in their cohorts or discussing
methods of developing diverse panel of reference genomes. The
difficulty of obtaining patients who meet criteria, are willing to
participate, and hit a diversity requirement is appreciated.
Regardless, it is entirely unacceptable to ignore racial disparity
due to the well documented nature of medical racism and GWS
must be carefully curated as it is developed to adapt and
overcome these racial biases to the absolute best ability.
First attempts at developing diverse reference panels are
promising. In an attempt to identify the rate of rare variants in a
target population, a study of 1070 genomes at a depth of 30x from
healthy Japanese citizens was conducted. The result was a highly
sensitive, population specific reference panel of variants. 21
million SNVs and over 3.4 million indels were identified with an
estimated false positive rate of <1%91. This project provides a
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model for the variant panels required for effective future genomic
testing.
5. CONCLUSIONS
Despite the legitimate hope raised for genome wide sequencing in
clinical practice for genetic counselors, significant hang-ups to
this process will prevent its use. Despite the current use within
some research and experimental clinics, the limitations prove too
great for ethical wide spread use. Before the use of GWS can
become widespread, there must be large scale studies evaluating
the efficacy of GWS in exome analysis as well as provide the
information necessary to get GWS testing covered by insurance
companies, large-scale population studies creating healthy panels
against which variants can be measured, institutional policies
relating to consent and incidental findings, and trainings
developed for genetic counselors to give effective genomic
counseling. While the empirical evidence for the efficacy
genome-wide sequencing is critically underdeveloped, it is
difficult and possibly unethical to observe the morbidity reduction
for vulnerable patient populations and deny them this tool. Still,
the risk created by using underdeveloped methodologies which
are already predisposed for unequal use and lack regulation is too
great to establish use of GWS in clinical practice at this time.
6. METHODOLOGY
Initial studies for this literature review were gathered through a
methodological search of the PubMed database with the keywords
‘genome-wide sequencing’ ‘genetic counseling’ and included
studies investigating genome wide sequencing for clinical use and
those which provided data or discourse on genetic counseling for
genome wide studies. An additional search for “genomic
counseling” was conducted, with all articles discussing both
genome sequencing and genetic counseling included. Search
parameters excluded papers published before the 2014 due to
technological limitations and any non-human subjects. Studies
were additionally excluded if GWS was conducted using PCR
methods, or if GWS comprised less than 10% of the overall study
data. Bibliographies of research papers were scanned for relevant
articles and to investigate broad claims. Individual articles were
sourced to provide evidence for relevant information not directly
related to GWS, EWS, or CMA, these articles were pulled from
other bibliographies or articles published <3 years ago in
high-impact journals from PubMed database searches. Additional
searches for specific sections of the paper were conducted in the
following sections with the parameters listed below.
Figure 1: PubMed keyword search “diagnostic success
rate of exome sequencing” with the filters “human” “english”
applied. Studies published before 2011 or not directly conducting
research on the diagnostic rate of exome sequencing were
excluded.
Figure 2: PubMed keyword search “diagnostic success
rate of whole genome sequencing” with the filters “human”
“english” applied. Studies published before 2014 or not directly
conducting research on the diagnostic rate of genome sequencing
were excluded.
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